The Modified Heparin-Binding l-Asparaginase of Wolinella succinogenes
- 199 Downloads
The modified asparaginase Was79 was derived from the recombinant wild-type l-asparaginase of Wolinella succinogenes. The Was79 contains the amino acid substitutions V23Q and K24T responsible for the resistance to trypsinolysis and the N-terminal heparin-binding peptide KRKKKGKGLGKKR responsible for the binding to heparin and tumor K562 cells in vitro. When tested on a mouse model of Fischer lymphadenosis L5178Y, therapeutic efficacy of Was79 was significantly higher than that of reference enzymes at all single therapeutic doses used (125–8000 IU/kg). At Was79 single doses of 500–8000 IU/kg, the complete remission rate of 100 % was observed. The Was79 variant can be expressed intracellularly in E. coli as a less immunogenic formyl-methionine-free form at high per cell production levels.
Keywordsl-Asparaginase Wolinella succinogenes Reduced glutaminase activity Trypsinolysis resistance Anti-tumor activity Heparin-binding
This work was supported by the Ministry of Education and Science of RF (State contract No. 14.N08.11.0014).
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflicts of interest.
All applicable international, national, and institutional guidelines for the care and use of animals were followed.
- 1.Durden, D. L., & Distasio, J. A. (1980). Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes. Cancer Research, 40, 1125–1129.Google Scholar
- 6.Distasio, J. A., Niederman, R. A., Kafkewitz, D., & Goodman, D. (1976). Purification and characterization of l-asparaginase with anti-lymphoma activity from Vibrio succinogenes. Journal of Biological Chemistry, 251, 6929–6933.Google Scholar
- 14.Thompson, S. A., Higashiyama, S., Wood, K., Pollitt, N. S., Damm, D., McEnroe, G., et al. (1994). Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. Journal of Biological Chemistry, 269, 2541–2549.Google Scholar
- 18.Dawson, R. M. C., Elliott, D. C., Elliott, W. H., & Jones, K. M. (1986). Data for biochemical research (3rd ed.). Oxford: Clarendon Press.Google Scholar
- 19.The, T. H., & Feltkamp, T. E. W. (1970). Conjugation of fluorescein isothiocyanate to antibodies. I. Experiments on the conditions of conjugation. Immunology, 18, 865–873.Google Scholar
- 20.Chabner, B. A., & Longo, D. L. (Eds.). (2001). Cancer chemotherapy and biotherapy: Principles and practice (3rd ed.). Philadelphia: Lippincott Williams & Wilkins.Google Scholar
- 24.Burchenal, J. H., Benvenisti, D., & Dollinger, M. (1970). Experimental studies with l-asparaginase in mouse leukemias. In E. Grundmann & H. F. Oettgen (Eds.), Experimental and clinical effects of l -asparaginase (Vol. 33, pp. 102–113)., Recent results in cancer research Berlin: Springer.CrossRefGoogle Scholar
- 28.Wriston, J. C, Jr, & Yellin, T. O. (1973). l-asparaginase: A review. Advances in Enzymology and Related Areas of Molecular Biology, 39, 185–248.Google Scholar
- 31.Domenech, C., Thomas, X., Chabaud, S., Baruchel, A., Gueyffier, F., Mazingue, F., et al. (2011). l-Asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. British Journal of Haematology, 153, 58–65.CrossRefGoogle Scholar
- 32.Agrawal, V., Woo, J. H., Borthakur, G., Kantarjian, H., & Frankel, A. E. (2013). Red blood cell-encapsulated l-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein and Peptide Letters, 20, 392–402.Google Scholar